ConductScience.org, home

Paper22326673

Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy.

Liu SH and 1 other. J Ethnopharmacol, 2012. Cited by 115 papers, by iCite.

Cite this record

ConductScience Library. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. Papers, record 22326673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22326673

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy.
PubMed
Journal
J Ethnopharmacol
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
115
iCite
Relative citation ratio, by iCite
3.9
iCite
Revised in PubMed
2024-01-09
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu SHShwu-Huey
2Cheng YCYung-Chi

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, PhytogenicMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
Drugs, Chinese HerbalMajor topic
MagnoliopsidaMajor topic
NeoplasmsMajor topic
PhytotherapyMajor topic
Plants, MedicinalMajor topic
Animals
Chemotherapy, Adjuvant
Drug Synergism
Drug Therapy, Combination
Humans

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
1P01CA154295-01NCI NIH HHSUnited StatesP01CA154295PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04000737YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by66

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.

PMIDTitleJournalYearIn PapersSource
41696740Huang-qin decoction increases the sensitivity of EGFR-TKIs to NSCLC cells by regulating stat3/GPX4 to induce redox ratio and ROS to inhibit CSCs.J Tradit Complement Med2026https://conductscience.org/library/papers/41696740PubMed
40978061The advantages of TCM in the treatment of gynecologic malignancies.Front Oncol2025https://conductscience.org/library/papers/40978061PubMed
40732339
Integration of Untargeted Metabolomics, Network Pharmacology, Single-Cell RNA Sequencing, and Molecular Dynamics Simulation Reveals GOT1, CYP1A2, and CA2 as Potential Targets of Huang Qin Decoction Preventing Colorectal Cancer Liver Metastasis.
Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40732339PubMed
39996849Areca catechu L. Extract Inhibits Colorectal Cancer Tumor Growth by Modulating Cell Apoptosis and Autophagy.Curr Issues Mol Biol2025https://conductscience.org/library/papers/39996849PubMed
39696809Exploration of In Situ Extraction for Enhanced Triterpenoid Production by Saccharomyces cerevisiae.Microb Biotechnol2024https://conductscience.org/library/papers/39696809PubMed
39691196Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment.Heliyon2024https://conductscience.org/library/papers/39691196PubMed
39354529Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.Mol Cancer2024https://conductscience.org/library/papers/39354529PubMed
39139999Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor.J Pharm Anal2024https://conductscience.org/library/papers/39139999PubMed
38956673An optimal combination of four active components in Huangqin decoction for the synergistic sensitization of irinotecan against colorectal cancer.Chin Med2024https://conductscience.org/library/papers/38956673PubMed
38814918Harnessing controlled-environment systems for enhanced production of medicinal plants.J Exp Bot2025https://conductscience.org/library/papers/38814918PubMed
38791314Puerarin Modulates Hepatic Farnesoid X Receptor and Gut Microbiota in High-Fat Diet-Induced Obese Mice.Int J Mol Sci2024https://conductscience.org/library/papers/38791314PubMed
38375031The effective combination therapies with irinotecan for colorectal cancer.Front Pharmacol2024https://conductscience.org/library/papers/38375031PubMed
38232757Evidence and possible mechanism of Scutellaria baicalensis and its bioactive compounds for hepatocellular carcinoma treatment.Ann Med2023https://conductscience.org/library/papers/38232757PubMed
38099482Current Characteristics of Herbal Medicine Interventions for Cancer on Clinical Databases: A Cross-Sectional Study.Integr Cancer Ther2023https://conductscience.org/library/papers/38099482PubMed
38079061Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview.Curr Treat Options Oncol2023https://conductscience.org/library/papers/38079061PubMed
37664157Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway.World J Gastroenterol2023https://conductscience.org/library/papers/37664157PubMed
37592799Herbal Medicines as Adjuvants for the Treatment of Chemotherapy-Induced Diarrhea.Curr Drug Metab2023https://conductscience.org/library/papers/37592799PubMed
37242514Synergistic Effects of Caffeine in Combination with Conventional Drugs: Perspectives of a Drug That Never Ages.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37242514PubMed
36686648YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.Front Pharmacol2022https://conductscience.org/library/papers/36686648PubMed
36440293East Wind, West Wind: Toward the modernization of traditional Chinese medicine.Front Neurosci2022https://conductscience.org/library/papers/36440293PubMed

See all 66 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22326673

GET https://conductscience.org/api/papers/v1/22326673/cited_by?page=2